What is the Carfilzomib?

Carfilzomib is , while it's Molecular Formula is C 40 H 57 N 5 O 7 . Carfilzomib is a second-generation proteasome inhibitor that is used as a treatment in relapsed and refractory multiple myeloma.

What is the CAS number for Carfilzomib?

The CAS number of Carfilzomib is 868540-17-4.

What is Carfilzomib (868540-17-4) used for?

In July 2012, the US FDA approved carfilzomib (also referred to as PR-171) for the treatment of patients with multiple myeloma (MM) who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression within 60 days of completion of the last therapy. Carfilzomib binds to and irreversibly inhibits the chymotrypsin-like protease activity of the constitutive proteosome (β5) and immunoproteosome (β5i) via its epoxyketone pharmacophore. Proteosome inhibition results in the accumulation of polyubiquitinated proteins and induction of apoptosis through activation of both the intrinsic and extrinsic caspase pathways. Carfilzomib inhibits chymotrypsin activity with an IC50 of 6 nM and is less potent an inhibitor of trypsin and caspase (IC50s of 3600 and 2400 nM, respectively). Cell cycle arrest and apoptosis are seen in a variety of hematologic and solid tumor cell lines (e.g.,MM, acutemyeloid leukemia (AML), pancreatic cancer, lung cancer) treated with carfilzomib. The synthesis of carfilzomib is reported in the patent literature and a route to the intermediate epoxy ketone from a Boc-leucine-derived α,β-unsaturated ketone is also described.InChI:InChI=1/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1

What is the Carfilzomib?

Carfilzomib is , while it's Molecular Formula is C 40 H 57 N 5 O 7 . Carfilzomib is a second-generation proteasome inhibitor that is used as a treatment in relapsed and refractory multiple myeloma.

What is the CAS number for Carfilzomib?

The CAS number of Carfilzomib is 868540-17-4.

What is Carfilzomib (868540-17-4) used for?

In July 2012, the US FDA approved carfilzomib (also referred to as PR-171) for the treatment of patients with multiple myeloma (MM) who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression within 60 days of completion of the last therapy. Carfilzomib binds to and irreversibly inhibits the chymotrypsin-like protease activity of the constitutive proteosome (β5) and immunoproteosome (β5i) via its epoxyketone pharmacophore. Proteosome inhibition results in the accumulation of polyubiquitinated proteins and induction of apoptosis through activation of both the intrinsic and extrinsic caspase pathways. Carfilzomib inhibits chymotrypsin activity with an IC50 of 6 nM and is less potent an inhibitor of trypsin and caspase (IC50s of 3600 and 2400 nM, respectively). Cell cycle arrest and apoptosis are seen in a variety of hematologic and solid tumor cell lines (e.g.,MM, acutemyeloid leukemia (AML), pancreatic cancer, lung cancer) treated with carfilzomib. The synthesis of carfilzomib is reported in the patent literature and a route to the intermediate epoxy ketone from a Boc-leucine-derived α,β-unsaturated ketone is also described.InChI:InChI=1/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1

Product Class

868540-17-4

Product Name：Carfilzomib
Molecular Formula：C₄₀H₅₇N₅O₇
Purity：99%
Molecular Weight：719.922

Inquiry

Product Details:

CasNo： 868540-17-4

Molecular Formula： C₄₀H₅₇N₅O₇

Buy Quality Carfilzomib,Export 868540-17-4 Cheap Price

Molecular Formula:C₄₀H₅₇N₅O₇
Molecular Weight:719.922
Vapor Pressure:0mmHg at 25°C
Refractive Index:1.551
Boiling Point:975.627 °C at 760 mmHg
PKA:13.17±0.46(Predicted)
Flash Point:543.84 °C
PSA：158.47000
Density:1.162g/cm³
LogP:4.08500

Carfilzomib(Cas 868540-17-4) Usage

Category	Carfilzomib is classified under proteasome inhibitors, a class of drugs used primarily in cancer treatment. It specifically targets the proteasome, a protein complex responsible for degrading unwanted or damaged proteins in cells.
Definition	Carfilzomib is a second-generation proteasome inhibitor used to treat relapsed and refractory multiple myeloma. It selectively and irreversibly binds to the chymotrypsin-like site of the proteasome, inhibiting its activity and inducing apoptosis in cancer cells.
Chemical Properties	Solubility: Limited water solubility, used in intravenous formulations Pharmacokinetics: Rapid metabolism, primarily by peptidase cleavage and epoxide hydrolysis. Cytochrome P450 mechanisms play a minor role in its metabolism.
Originator	Proteolix Inc. (United States)
Uses	Commonly combined with dexamethasone or with lenalidomide plus dexamethasone to enhance treatment efficacy in multiple myeloma patients after 1-3 prior lines of treatment. Approved for the treatment of relapsed and refractory multiple myeloma in patients who have not responded to prior treatments. It can be used alone to treat multiple myeloma.
Brand name	Kyprolis
Side Effects	Common Side Effects (≥30% occurrence in trials): Fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, fever. Serious Adverse Events (45% incidence): Pneumonia, acute renal failure, congestive heart failure, fever. Neuropathy: Minimal compared to other proteasome inhibitors, representing a potential advantage.
Clinical Studies	Carfilzomib has shown strong antitumor activity in hematologic malignancies, with a manageable safety profile, and is being studied in various other cancer types, either alone or in combination with other agents.

InChI:InChI=1/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1

868540-17-4 Relevant articles

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

List of authors. A. Keith Stewart, M.B., Ch.B., S. Vincent Rajkumar, M.D., Meletios A. Dimopoulos, M.D., Tamás Masszi, M.D., Ph.D., Ivan Špička, M.D., Ph.D., Albert Oriol, M.D., Roman Hájek, M.D., Ph.D., Laura Rosiñol, M.D., Ph.D., David S. Siegel, M.D., Ph.D., Georgi G. Mihaylov, M.D., Ph.D., Vesselina Goranova-Marinova, M.D., Ph.D., Péter Rajnics, M.D., Ph.D.

N Engl J Med 2015; 372:142-152

We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival.

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

Thomas M. Herndon; Albert Deisseroth; Edvardas Kaminskas; Robert C. Kane; Kallappa M. Koti; Mark D. Rothmann; Bahru Habtemariam; Julie Bullock; Jeffrey D. Bray; Jessica Hawes; Todd R. Palmby; Josephine Jee; William Adams; Houda Mahayni; Janice Brown; Angelica Dorantes; Rajeshwari Sridhara; Ann T. Farrell; Richard Pazdur

Clin Cancer Res (2013) 19 (17): 4559–4563.

The safety of carfilzomib was evaluated in 526 patients with multiple myeloma treated with various dosing regimens. The ORR was 23%. The median duration of response was 7.8 months. The most common adverse reactions associated with carfilzomib infusion were fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and fever.

868540-17-4 Process route

: 247068-81-1
tert-butyl [(1S)-3-methyl-1-(2-methylpropyl)-2-oxobut-3-en-1-yl]carbamate

: 868540-17-4
carfilzomib

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1: calcium hypochlorite / water; 1-methyl-pyrrolidin-2-one / 0.33 h / -15 - 0 °C 2: dichloromethane / 2 h / 0 - 20 °C / Inert atmosphere 3: benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate / N,N-dimethyl-formamide / 1.5 h / 0 - 5 °C With calcium hypochlorite; benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In 1-methyl-pyrrolidin-2-one; dichloromethane; water; N,N-dimethyl-formamide;
Multi-step reaction with 3 steps 1: sodium hypochlorite; pyridine / water / 2 h / -5 - 0 °C 2: dichloromethane / 2 h / 0 - 20 °C / Inert atmosphere 3: benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate / N,N-dimethyl-formamide / 1.5 h / 0 - 5 °C With pyridine; sodium hypochlorite; benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In dichloromethane; water; N,N-dimethyl-formamide;
Multi-step reaction with 3 steps 1: potassium carbonate; benzonitrile; dihydrogen peroxide / methanol / 6 h / 25 - 30 °C 2: trifluoroacetic acid / dichloromethane / 3 h / 5 - 10 °C / Inert atmosphere 3: dichloromethane / 1 h With dihydrogen peroxide; potassium carbonate; benzonitrile; trifluoroacetic acid; In methanol; dichloromethane;
Multi-step reaction with 3 steps 1: potassium carbonate; benzonitrile; dihydrogen peroxide / methanol / 6 h / 25 - 30 °C 2: trifluoroacetic acid / dichloromethane / 3 h / 5 - 10 °C / Inert atmosphere 3: dichloromethane / 3 h / 25 - 30 °C With dihydrogen peroxide; potassium carbonate; benzonitrile; trifluoroacetic acid; In methanol; dichloromethane;
Multi-step reaction with 5 steps 1: cerium(III) chloride heptahydrate; sodium tetrahydroborate / methanol / 1 h / 0 - 5 °C 2: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 0 - 30 °C 3: Dess-Martin periodane / acetonitrile / 3 h / 0 - 30 °C 4: dichloromethane / 2 h / 2 - 30 °C 5: benzotriazol-1-ol; benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / acetonitrile / 0 - 5 °C / Inert atmosphere With sodium tetrahydroborate; cerium(III) chloride heptahydrate; benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; benzotriazol-1-ol; Dess-Martin periodane; N-ethyl-N,N-diisopropylamine; 3-chloro-benzenecarboperoxoic acid; In methanol; dichloromethane; acetonitrile;
Multi-step reaction with 6 steps 1.1: cerium(III) chloride heptahydrate; sodium tetrahydroborate / methanol / 1 h / 0 - 5 °C 2.1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 0 - 30 °C 3.1: Dess-Martin periodane / acetonitrile / 3 h / 0 - 30 °C 4.1: dichloromethane / 2 h / 2 - 30 °C 5.1: benzotriazol-1-ol; benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / acetonitrile / -10 - -5 °C 5.2: 0.5 h / 25 - 30 °C 6.1: sodium hydrogencarbonate / dichloromethane; water / 0.17 h / 2 - 6 °C With sodium tetrahydroborate; cerium(III) chloride heptahydrate; benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; sodium hydrogencarbonate; benzotriazol-1-ol; Dess-Martin periodane; N-ethyl-N,N-diisopropylamine; 3-chloro-benzenecarboperoxoic acid; In methanol; dichloromethane; water; acetonitrile;
Multi-step reaction with 8 steps 1.1: cerium(III) chloride heptahydrate; sodium tetrahydroborate / methanol / 1 h / 0 - 5 °C 2.1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 0 - 30 °C 3.1: Dess-Martin periodane / acetonitrile / 3 h / 0 - 30 °C 4.1: dichloromethane / 2 h / 2 - 30 °C 5.1: benzotriazol-1-ol; benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 2 - 6 °C 6.1: trifluoroacetic acid / dichloromethane / 2 - 6 °C 7.1: benzotriazol-1-ol; benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 2 - 6 °C 7.2: 0.5 h / 25 - 30 °C 8.1: sodium hydrogencarbonate / dichloromethane; water / 0.17 h / 2 - 6 °C With sodium tetrahydroborate; cerium(III) chloride heptahydrate; benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; sodium hydrogencarbonate; benzotriazol-1-ol; Dess-Martin periodane; N-ethyl-N,N-diisopropylamine; 3-chloro-benzenecarboperoxoic acid; trifluoroacetic acid; In methanol; dichloromethane; water; N,N-dimethyl-formamide; acetonitrile;

: 868540-16-3
(S)-2-((S)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamido)-3-phenyipropanoic acid

: C₉H₁₇NO₂*C₃HF₅O₂

: 868540-17-4
carfilzomib